Pharmafile Logo

Biosimilars: Bringing patients into the conversation

Published in eyeforpharma January 2017 by Mariel Metcalfe


In a recent white paper, we explored the impact that biosimilars are having and likely to have on the rising cost of RA treatment. We looked at physician attitudes to biosimilars and the challenges manufacturers face in gaining widespread acceptance. 

There’s no doubt that the cheaper cost of biosimilars versus their originator biologic, even though not as substantial as generics, make them very attractive to healthcare markets. But so far, biosimilar manufacturers have dedicated most of their efforts to convincing payers of these cost benefits, seeing them as the primary gatekeeper of market access. However, by focusing just on payers, are they missing a trick? In the longer-term, manufacturers could benefit from educating and winning over a wider audience, and not just physicians, but also patients…

http://www.researchpartnership.com/news/2016/09/article-biosimilars-bringing-patients-into-the-conve…

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Quantitative specialist joins Research Partnership, London

Global healthcare market research consultancy Research Partnership has appointed Roy Rogers as a Quantitative Director in their UK offices in London

Webcast

Amplifying the patient voice: How to conduct patient research sensitively to uncover emotional insights

Webcast

The power of a good story: Turn your insights into effective storytelling with data visualisation

Article

How will COVID-19 affect uptake of vaccinations against other diseases?

Podcast

Living With Chronic Illness (Series one)

Webcast

China: How pharma can maximize success in this rapidly changing emerging market

Article

Inhale, Exhale: The struggle of living with Severe Asthma and Severe Eosinophilic Asthma

Infographic

Migraine market snapshot

Webcast

Monitoring the impact of COVID-19 on the market access landscape

Live webinar from Singapore

Digital #marcomms: How to evaluate and optimise marketing activities impacted by COVID-19